TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01193608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 0.5 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 1 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 2 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 4 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 8 mg/kg AAB-003, IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, IV
Study: NCT01714843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT04097158

Intervention type: OTHER
Intervention: Sample Collection
Description: The investigators will be collecting blood, urine, and spinal fluid samples.

Intervention type: OTHER
Intervention: Sample Collection
Description: The investigators will be collecting blood, urine, and spinal fluid samples.

Intervention type: OTHER
Intervention: Sample Collection
Description: The investigators will be collecting blood, urine, and spinal fluid samples.

Intervention type: OTHER
Intervention: Sample Collection
Description: The investigators will be collecting blood, urine, and spinal fluid samples.
Study: NCT05969366

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Study: NCT03221426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT05427097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helical® patches
Description: Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
Study: NCT03221426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study: NCT00953420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes
Description: 1 x 10e8 cells/m2 IV over 1 to 5 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF or Peg-GCSF
Description: If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for \> 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC \> 2500 cells/ul x 2 days after nadir.
Study: NCT01586338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: Intra-articular injection (pre-filled glass syringe)
Study: NCT01436123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stenting and micro-infusion of NP
Description: Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting stent
Description: Put stent in ischemia-related coronary artery by indications for PCI
Study: NCT00453102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan
Description: IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
Study: NCT05171140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triangular Nail Placement of Femoral Neck
Description: Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triangular Nail Placement of Femoral Neck
Description: Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
Study: NCT03051659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
Study: NCT02660762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
Study: NCT05427097

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Helical® patches
Description: Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
Study: NCT02872649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Study: NCT02660762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Description: induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal cytarabine
Description: 50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
Study: NCT00900575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Spectroscopy Bench-Top System
Description: This device is a bench-top optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Optical Spectrometer
Description: This device is a portable optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal colposcope
Study: NCT04362137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 5 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-image placebo
Study: NCT03757806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts.
Study: NCT03497884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
Study: NCT00829361

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Two way site independent audio/video telemedicine system with DICOM.
Study: NCT01763528

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Description: high protein diet
Study: NCT03862703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth intervention, PTSD Help app.
Description: Experimental group will receive the app, PTSD Help.
Study: NCT00785538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study: NCT02562963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer T cell
Description: The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
Study: NCT03221426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: IV infusion
Study: NCT04114357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylated and Butyrylated High Amylose Maize Starch
Description: Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
Study: NCT06405789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga practice
Description: The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
Study: NCT00514904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax
Description: Single dose, subcutaneous injection
Study: NCT02284568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules in 0.5 mg and 0.6 mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules in 0.5 mg and 0.6 mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study: NCT01037127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Daily oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Daily oral dosing
Study: NCT00006024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT00734695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: Subconjunctival daily or bid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: topical and systemic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: topical systemic
Study: NCT03363451

Intervention type: DRUG
Intervention: Antibiotics
Description: This is an observation study, no specific antibiotics will be indicated during treatment
Study: NCT03426436

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Two consecutive 15-lead ECGs
Description: The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
Study: NCT03652636

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfur Hexafluoride Microspheres
Description: 2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
Study: NCT02573766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback Training
Description: Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback Training
Description: Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Scale
Description: Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pain Scale
Description: Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Study: NCT04055376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham Settings)
Description: Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months.
Study: NCT03898362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pneumatically powered wheelchair or scooter
Description: a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: battery powered wheelchair or scooter
Description: a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
Study: NCT04398654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMEMSTM HF sensor - pulmonary artery pressure measurement
Description: CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.